• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Kenvue Announces Chief Financial Officer Transition

    5/8/25 6:45:00 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary
    Get the next $KVUE alert in real time by email
    • Amit Banati, 30-Year Consumer Products Company Finance and Operations Veteran, Appointed CFO
    • Succeeds Paul Ruh, Effective May 12, 2025

    Kenvue Inc. (NYSE:KVUE), today announced the appointment of Amit Banati as the Company's Chief Financial Officer, effective May 12, 2025. He will be responsible for overseeing the Finance and Strategy functions, supporting initiatives aimed at accelerating profitable growth and delivering value to shareholders. Following a thorough and thoughtful search process, Mr. Banati will succeed Paul Ruh, who will remain with the Company for a brief period to help ensure a smooth transition.

    Mr. Banati is a 30-year consumer products company finance and operations veteran, having served most recently as Vice Chairman and Chief Financial Officer of Kellanova (previously Kellogg Company), and holding finance and operating leadership roles at Kraft Foods (now Mondelez International), Cadbury Schweppes and Procter & Gamble. He has significant experience overseeing operations outside the U.S., including in Asia Pacific, the Middle East, India and Africa, and has successfully delivered profitable growth and executed enterprise-wide business transformations.

    "We are thrilled to welcome Amit to Kenvue and look forward to leveraging his deep industry expertise and business transformation experience as we continue to focus on accelerating Kenvue's profitable growth and delivering value for shareholders," said Thibaut Mongon, Chief Executive Officer. "With much of the work to establish Kenvue as an independent company completed and our strengthened commercial and operational foundations in place, now is the right time for a CFO transition. Amit is a world-class executive with a proven track record across both financial and operational roles and the ideal person to further support our efforts to work differently and move faster and lead our Finance and Strategy organizations into the future."

    "I am excited to join Kenvue with its global scale and portfolio of iconic consumer health brands," Mr. Banati said. "My focus as CFO will be supporting revenue growth through stronger data management and resource allocation, driving continued margin and cost profile improvement efforts, strengthening cash flow, and fostering greater agility, including better integrated business planning and improved financial forecasting. With the talented Kenvuers around the world, we can maximize benefits of the Company's increased brand investments and accelerate growth across Self Care, Skin Health and Beauty, and Essential Health to create sustainable value for shareholders."

    Mr. Mongon added, "On behalf of the entire organization and our Board of Directors, I thank Paul for his many contributions in helping execute one of the largest separations in public company history to establish Kenvue as a standalone leader in consumer health. He stood up the Our Vue Forward transformation program and helped shape our P&L to allow us to invest more behind our brands, setting the stage for accelerated growth. We wish Paul all the best in his next chapter."

    In a separate press release this morning, the Company announced financial results for the fiscal first quarter ended March 30, 2025. Additional details regarding the Company's earnings results can be found at investors.kenvue.com.

    About Amit Banati

    Most recently, Mr. Banati served as Vice Chair and Chief Financial Officer at Kellanova (Kellogg), where he was responsible for all financial operations and led strategy and business development, including M&A and a venture capital fund. As CFO at Kellogg (2019-2022), he led the business through a period of significant transformation, implementing and evolving the company's Deploy For Growth strategy, which enabled Kellogg's return to sustainable, profitable growth. And as Region President at Kellogg (2012-2019), he was the driving force behind the transformation of the company's Asia, Middle East and Africa business, more than doubling net sales and operating profit.

    Previously, Mr. Banati held finance and general management roles at Kraft Foods, Cadbury Schweppes and Procter & Gamble. At Kraft Foods, he was President, North Asia and Asia Pacific Strategy, and led the integration of Cadbury and Kraft Foods for that region. At Cadbury Schweppes, he was President of the Pacific region, overseeing Australia, New Zealand, Japan and Singapore, and served previously as the company's Chief Financial Officer of the Asia Pacific division. At Procter & Gamble, he spent nearly 15 years in finance roles, rising to become Chief Financial Officer of the Asean, Australia, India, Singapore region in the company's Health and Beauty Care division. He received a bachelor's degree in commerce from Calcutta University and an MBA from the Indian Institute of Management in Lucknow. Mr. Banati also currently serves on the Board of Fortune Brands Innovations.

    About Kenvue

    Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's®, Listerine®, Neutrogena®, and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue, we realize the extraordinary power of everyday care. Our teams work every day to put that power in consumers' hands and earn a place in their hearts and homes. Learn more at www.kenvue.com.

    Cautions Concerning Forward-Looking Statements

    This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding Kenvue's Chief Financial Officer transition. Forward-looking statements may be identified by the use of words such as "plans," "expects," "will," "anticipates," "estimates" and other words of similar meaning. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Kenvue Inc. ("Kenvue") and its affiliates.

    A list and descriptions of risks, uncertainties and other factors can be found in Kenvue's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 29, 2024 and subsequent Quarterly Reports on Form 10-Q and other filings, available at www.kenvue.com or on request from Kenvue. Kenvue and its affiliates undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or developments or otherwise.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250508263505/en/

    Melissa Witt

    [email protected]

    Get the next $KVUE alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KVUE

    DatePrice TargetRatingAnalyst
    4/10/2025$23.50Neutral
    Redburn Atlantic
    3/24/2025$25.00In-line
    Evercore ISI
    1/6/2025$21.00 → $26.00Neutral → Overweight
    Piper Sandler
    12/12/2024$25.00 → $24.00Buy → Hold
    Deutsche Bank
    9/24/2024$27.00Buy
    Jefferies
    9/24/2024$24.00Outperform → Sector Perform
    RBC Capital Mkts
    5/28/2024$21.00Neutral
    Citigroup
    4/11/2024$18.00Underperform
    Bernstein
    More analyst ratings

    $KVUE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Group President APAC Dasgupta Anindya

    4 - Kenvue Inc. (0001944048) (Issuer)

    8/27/25 7:14:16 PM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    SEC Form 3 filed by new insider Dasgupta Anindya

    3 - Kenvue Inc. (0001944048) (Issuer)

    8/27/25 7:11:46 PM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    SEC Form 3 filed by new insider Wondrasch Michael

    3 - Kenvue Inc. (0001944048) (Issuer)

    8/27/25 4:50:57 PM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    $KVUE
    Leadership Updates

    Live Leadership Updates

    View All

    Kenvue Announces CEO Transition and Actions to Unlock Shareholder Value

    Appoints Current Kenvue Director and Proven CPG and Technology Company Leader, Kirk Perry, as Interim CEO, Effective Immediately Announces Ongoing Review of Strategic Alternatives Reports Select Preliminary Second Quarter 2025 Financial Results Kenvue Inc. (NYSE:KVUE) today announced that its Board of Directors is implementing a set of actions to enable the Company to unlock shareholder value and reach its full potential. The Board has made a Chief Executive Officer transition and is advancing an ongoing comprehensive review of strategic alternatives. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250714520711/en/Kirk

    7/14/25 6:45:00 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Kenvue Debuts on Fortune 500 List

    Kenvue Inc. (NYSE:KVUE), maker of consumer health products like Tylenol®, Neutrogena® and Listerine®, today announced it has made the prestigious Fortune 500 list for the first time since becoming a fully independent company. With 2024 full year sales of $15.5 billion, Kenvue is listed at number 281. The company's debut is a testament to the power of its iconic brands and deep commitment to improving the health and well-being of consumers globally through science-backed, insights-led innovation. "Being named to the Fortune 500 list marks a significant milestone for Kenvue," said Thibaut Mongon, Chief Executive Officer. "Recognitions like this validate the hard work and dedication of our K

    6/2/25 6:15:00 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Kenvue Announces Chief Financial Officer Transition

    Amit Banati, 30-Year Consumer Products Company Finance and Operations Veteran, Appointed CFO Succeeds Paul Ruh, Effective May 12, 2025 Kenvue Inc. (NYSE:KVUE), today announced the appointment of Amit Banati as the Company's Chief Financial Officer, effective May 12, 2025. He will be responsible for overseeing the Finance and Strategy functions, supporting initiatives aimed at accelerating profitable growth and delivering value to shareholders. Following a thorough and thoughtful search process, Mr. Banati will succeed Paul Ruh, who will remain with the Company for a brief period to help ensure a smooth transition. Mr. Banati is a 30-year consumer products company finance and operation

    5/8/25 6:45:00 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    $KVUE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Redburn Atlantic initiated coverage on Kenvue with a new price target

    Redburn Atlantic initiated coverage of Kenvue with a rating of Neutral and set a new price target of $23.50

    4/10/25 12:41:58 PM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Evercore ISI initiated coverage on Kenvue with a new price target

    Evercore ISI initiated coverage of Kenvue with a rating of In-line and set a new price target of $25.00

    3/24/25 8:39:49 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Kenvue upgraded by Piper Sandler with a new price target

    Piper Sandler upgraded Kenvue from Neutral to Overweight and set a new price target of $26.00 from $21.00 previously

    1/6/25 8:13:28 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    $KVUE
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Kenvue Inc.

    SCHEDULE 13G/A - Kenvue Inc. (0001944048) (Subject)

    8/14/25 1:07:20 PM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    SEC Form 10-Q filed by Kenvue Inc.

    10-Q - Kenvue Inc. (0001944048) (Filer)

    8/7/25 4:05:41 PM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Kenvue Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Kenvue Inc. (0001944048) (Filer)

    8/7/25 6:47:11 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    $KVUE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Kenvue Reports Second Quarter 2025 Results

    Net Sales (4.0)%; Organic Sales1 (4.2)% Diluted EPS was $0.22; Adjusted Diluted EPS1 was $0.29 Continues to Advance Ongoing Review of Strategic Alternatives, While Taking Actions to Accelerate Profitable Growth Under the New Executive Team Revises Outlook for FY'25 Kenvue Inc. (NYSE:KVUE) today announced financial results for the second quarter ended June 29, 2025. "Kenvue has a strong portfolio of world-class, category-defining brands. We are actively focused on improving execution and performance, while advancing the comprehensive strategic alternatives review, to deliver our inherent value," said Kirk Perry, Interim Chief Executive Officer. "I'm thrilled to take on this ne

    8/7/25 6:45:00 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Kenvue Increases Quarterly Cash Dividend

    Kenvue Inc. (NYSE:KVUE) today announced its Board of Directors declared a quarterly dividend of $0.2075 per share on its common stock, which represents a 1.2 percent increase compared to the prior quarterly dividend. The quarterly dividend is payable on August 27, 2025, to shareholders of record as of the close of business on August 13, 2025. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's®, Listerine®, Neutrogena® and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue, we realize the ex

    7/30/25 6:45:00 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Kenvue to Announce Second Quarter 2025 Results on August 7, 2025

    Kenvue Inc. (NYSE:KVUE) will announce its second quarter 2025 financial results before the market opens on August 7, 2025. The company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its financial results. The conference call can be accessed by dialing 877-407-8835 from the U.S. or +1 201-689-8779 from international locations. A live webcast of the conference call can also be accessed at investors.kenvue.com, with a replay made available after the live event. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's

    7/25/25 6:45:00 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    $KVUE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Kenvue Inc.

    SC 13G/A - Kenvue Inc. (0001944048) (Subject)

    11/14/24 1:22:40 PM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Kenvue Inc.

    SC 13G/A - Kenvue Inc. (0001944048) (Subject)

    11/12/24 10:32:12 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Kenvue Inc.

    SC 13G/A - Kenvue Inc. (0001944048) (Subject)

    10/16/24 10:07:52 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    $KVUE
    Financials

    Live finance-specific insights

    View All

    Kenvue Reports Second Quarter 2025 Results

    Net Sales (4.0)%; Organic Sales1 (4.2)% Diluted EPS was $0.22; Adjusted Diluted EPS1 was $0.29 Continues to Advance Ongoing Review of Strategic Alternatives, While Taking Actions to Accelerate Profitable Growth Under the New Executive Team Revises Outlook for FY'25 Kenvue Inc. (NYSE:KVUE) today announced financial results for the second quarter ended June 29, 2025. "Kenvue has a strong portfolio of world-class, category-defining brands. We are actively focused on improving execution and performance, while advancing the comprehensive strategic alternatives review, to deliver our inherent value," said Kirk Perry, Interim Chief Executive Officer. "I'm thrilled to take on this ne

    8/7/25 6:45:00 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Kenvue Increases Quarterly Cash Dividend

    Kenvue Inc. (NYSE:KVUE) today announced its Board of Directors declared a quarterly dividend of $0.2075 per share on its common stock, which represents a 1.2 percent increase compared to the prior quarterly dividend. The quarterly dividend is payable on August 27, 2025, to shareholders of record as of the close of business on August 13, 2025. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's®, Listerine®, Neutrogena® and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue, we realize the ex

    7/30/25 6:45:00 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Kenvue to Announce Second Quarter 2025 Results on August 7, 2025

    Kenvue Inc. (NYSE:KVUE) will announce its second quarter 2025 financial results before the market opens on August 7, 2025. The company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its financial results. The conference call can be accessed by dialing 877-407-8835 from the U.S. or +1 201-689-8779 from international locations. A live webcast of the conference call can also be accessed at investors.kenvue.com, with a replay made available after the live event. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's

    7/25/25 6:45:00 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary